Skip to main content

Sigma-Aldrich Revenues Increase for Q3, Boosted 4.6 Percent by Currency Exchange

NEW YORK, Oct. 21 (GenomeWeb News) - Sigma-Aldrich today reported net sales of $341 million for the quarter ended Sept. 30, up from $314 million for the same period last year.


The increase reflected a 4.6-percent benefit from currency exchange rates, the company said. Around half of  Sigma's sales are in currencies other than dollars, and its revenues reflect benefits from exchange rates.


Sigma's biotechnology business unit, which sells its product lines of molecular biology tools, reported sales of $75 million, up from $72 million for the year-ago quarter.


The St. Louis-based company had a gross profit of $182 million for the period, compared to $164 million for the year-ago quarter.


The firm had R&D expenses of $10.5 million for the quarter, compared to $10.2 million for the year-ago period.


Sigma finished the quarter with $134 million in cash and cash equivalents on hand, compared to $128 million for the year-ago quarter.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.